lupus therapeutics Archives

Tag: lupus therapeutics

How Are the New Lupus Nephritis Guidelines Impacting Treatment?

Recognized as National Kidney Month, March is the ideal time to learn more about the 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. Recently issued, the guidelines are designed to provide healthcare providers with up-to-date guidance on the care and treatment of adults and children with lupus […] Read More

LRA Forum for Discovery Showcases Cutting-Edge Lupus Research

The Lupus Research Alliance (LRA) hosted its highly anticipated annual scientific conference, Forum for Discovery (FFD), November 11-13 in New York City. A hallmark event for the lupus research community, FFD brings together LRA-funded investigators from across the globe to discuss the latest breakthroughs of their LRA-funded projects. Serving as a crucial platform for fostering […] Read More

Celebrating Native American Heritage Month: Meet Dr. Kent Kwoh, A Champion for Health Equity

During Native American Heritage Month, we celebrate a dedicated champion of health equity. As Chief of Rheumatology and Director of the Arthritis Center at University of Arizona, Dr. Kwoh is devoted to making sure the Indigenous people he treats receive the best possible care for their lupus. How? By listening, learning, and incorporating their perspectives […] Read More

Investigational Treatment Dapirolizumab Pegol Shows Positive Results in Phase 3 Clinical Trial

Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, is proud to share positive topline results from the Phase 3 PHOENYCS GO study evaluating the investigational therapy dapirolizumab pegol in people living with moderate-to-severe systemic lupus. Results of the Phase 3 PHOENYCS GO study were reported by study sponsors UCB and Biogen. The […] Read More

Inspired by Patient Need, Dermatologist Specializes in Cutaneous Lupus

Dr. Victoria Werth decided to focus her career on researching and treating cutaneous (skin) lupus erythematosus because she saw a major need that she could help fill. Her story is especially appropriate this July during Ultraviolet Safety Month – as ultraviolet sun rays can trigger flares for people with cutaneous and/or systemic lupus. When Dr. […] Read More

Meet Unstoppable Advocate for Minority Health Christopher Reed

Determined to alleviate healthcare disparities for minorities, J. Christopher Reed, JD, urges our lupus community to use the power of National Minority Health Month to spotlight the issue this April. First diagnosed at 16, Christopher fought debilitating lupus symptoms to graduate college in eight years and then Tulane University Law School in three. Throughout college […] Read More

Lupus Peer-to-Peer Early Education Program Expands

Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, has announced an innovative expansion of the highly successful Patient Advocates for Lupus Studies (PALS) program with the introduction of a first-in-lupus “Trial Buddy” component made possible by a partnership with Bristol Myers Squibb. The Trial Buddy addition provides extra support to people with […] Read More

Lupus Therapeutics Announces Collaboration to Support the Evaluation of Non-Genetically Modified Cell-Based Therapy for Lupus Nephritis with Artiva Biotherapeutics

Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, announced a collaboration with Artiva Biotherapeutics, Inc. on a Phase 1 trial of the company novel NK cell-based therapy AlloNK® (also known as AB-101), in combination with anti-CD20 antibodies, for patients with active lupus nephritis – inflammation of the kidneys caused by lupus. AlloNK […] Read More

Championing Patient Power in Lupus

Dr. Stacie Bell came to LRA’s clinical research affiliate Lupus Therapeutics (LT) one year ago to help fulfill the vision of an entire community united to triumph over a complex and confounding disease. She joined determined to work with the researchers, clinicians, biopharmaceutical companies, and most importantly the people with lupus and their families to […] Read More

LRA Highlights Groundbreaking Lupus Research at ACR Convergence 2023

This information is brought to you by the Lupus Research Alliance and Lupus Therapeutics and is not sponsored by, nor a part of, the American College of Rheumatology. 30+ presentations of studies funded by the LRA spanning a broad spectrum of research areas Positive results from Phase 2/3 clinical studies supported by LRA affiliate Lupus Therapeutics point to […] Read More

Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis

The clinical research affiliate of the Lupus Research Alliance, Lupus Therapeutics, announced a partnership with the biopharmaceutical company Nkarta, Inc. in developing the engineered natural killer (NK) cell therapy NKX019 as a potential treatment for people with refractory lupus nephritis who have not responded to standard treatment. Read More

To Increase Diversity in Lupus Clinical Research, Project CHANGE Launches Pilot Programs in Atlanta, Nashville, and Philadelphia

NEW YORK, NY, June 29, 2023 — The clinical research affiliate of the Lupus Research Alliance, Lupus Therapeutics, launched three pilot research initiatives for Project CHANGE, a community-driven approach to address systemic challenges contributing to the underrepresentation of people of color, particularly Black people, in lupus clinical trials. Emory University in Atlanta, Vanderbilt University in Nashville, […] Read More